Progentec Diagnostics

Progentec Diagnostics is pioneering a data-driven, proactive approach to managing autoimmune diseases by integrating molecular diagnostics (proteomics) with digital biomarkers and remote monitoring. Its flagship aiSLE® DX tests, available through Mayo Clinic Laboratories, predict lupus flare risk up to 12 weeks in advance. The company also operates a significant digital patient community and research platform (LupusCorner) and is expanding its pipeline into MS and other autoimmune conditions. Its business model leverages diagnostic test revenue and digital tools to improve patient outcomes and support decentralized clinical research.

Integrated proteomics and digital health platform. Proprietary `LiquidFlareRisk™` and `LiquidDiseaseActivity™` technologies for blood-based biomarker analysis, combined with the `LupusCorner®` digital ecosystem for patient engagement, remote monitoring, and decentralized clinical research.

Competes in the autoimmune diagnostics space with companies developing multi-omics and digital biomarkers. Differentiation lies in the integrated combination of a proprietary proteomic test with a dedicated digital patient community and remote monitoring platform. The Mayo Clinic partnership provides significant credibility and distribution advantage.